Tian'an Pharmaceutical Co., Ltd. (TNPH) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Tian'an Pharmaceutical Co., Ltd. (TNPH) trades at $0.009 with AI Score 42/100 (Grade C). Tian'an Pharmaceutical Co. , Ltd. is a Chinese company that develops, manufactures, and sells traditional Chinese herbal medicines. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for TNPH: TNPH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TNPH against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TNPH: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Tian'an Pharmaceutical Co., Ltd. (TNPH) Healthcare & Pipeline Overview
Tian'an Pharmaceutical Co., Ltd., based in China, focuses on traditional Chinese herbal medicines, offering products like capsules, granules, and ointments for various health conditions. Operating in the specialty and generic drug manufacturing sector, the company distributes its products through independent channels to pharmacies and hospitals.
What Is the Investment Thesis for TNPH?
Tian'an Pharmaceutical operates in the niche market of traditional Chinese medicine, presenting both opportunities and challenges. The company's focus on herbal remedies caters to a specific segment of the population that prefers traditional treatments. However, its small size and limited resources, with only 3 employees, pose significant operational constraints. The company's high P/E ratio of 1080.94 suggests that the market has high expectations for future growth, which may be difficult to achieve given its current scale. The negative beta of -2.35 indicates an inverse correlation with the market, which could offer some downside protection during market downturns. The absence of a dividend yield means investors are relying solely on capital appreciation for returns. Upcoming regulatory changes in the pharmaceutical industry and the potential success of its pain relief capsule currently under development could serve as catalysts. However, competition from larger pharmaceutical companies and potential quality control issues remain significant risks.
Based on FMP financials and quantitative analysis
TNPH Key Highlights
Tian'an Pharmaceutical specializes in traditional Chinese herbal medicines, catering to a specific market segment.
- The company's P/E ratio is exceptionally high at 1080.94, reflecting significant investor expectations.
- With only 3 employees, the company faces operational constraints and scalability challenges.
- The company's beta is -2.35, indicating a negative correlation with the broader market.
- Tian'an Pharmaceutical does not offer a dividend, meaning returns are based on capital appreciation.
Who Are TNPH's Competitors?
TNPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TNPH's Key Strengths?
Specialization in traditional Chinese medicine.
- Established distribution network in China.
- Proprietary herbal formulations.
- Focus on specific health conditions.
What Are TNPH's Weaknesses?
Small company size with limited resources.
- High P/E ratio indicating high market expectations.
- Dependence on independent distributors.
- Limited geographic reach.
What Could Drive TNPH Stock Higher?
Potential regulatory approval of Tianan Pain Relief Capsule.
- Increasing demand for traditional Chinese medicine in China.
- Expansion of distribution network through strategic partnerships.
What Are the Key Risks for TNPH?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Competition from larger pharmaceutical companies.
- Regulatory changes impacting the traditional medicine industry.
- Quality control issues with herbal formulations.
- Limited financial resources and small company size.
- Dependence on independent distributors.
What Are the Growth Opportunities for TNPH?
- Expanding Product Line: Tian'an Pharmaceutical has the opportunity to broaden its product line beyond its current offerings. Developing new herbal formulations targeting prevalent health issues in China, such as diabetes or cardiovascular diseases, could significantly increase its market reach. The market for diabetes treatments in China, for instance, is projected to reach $20 billion by 2028, presenting a substantial opportunity for the company to capture a share of this market with innovative herbal remedies. Timeline: 2-3 years.
- Geographic Expansion: Currently focused on the Chinese market, Tian'an Pharmaceutical could explore opportunities to expand into other Asian countries with a strong tradition of herbal medicine, such as Vietnam, Korea, and Thailand. These markets share cultural similarities and a preference for traditional remedies, making them potentially receptive to the company's products. The Southeast Asian herbal medicine market is estimated at $10 billion annually. Timeline: 3-5 years.
- Strategic Partnerships: Forming strategic partnerships with established pharmaceutical distributors or healthcare providers could enhance Tian'an Pharmaceutical's market access and distribution capabilities. Collaborating with a major hospital chain in China, for example, could provide a direct channel to reach a large patient base. Such partnerships can also facilitate the development and marketing of new products. Timeline: 1-2 years.
- Online Sales Channels: Establishing a strong online presence through e-commerce platforms and direct-to-consumer sales could significantly expand Tian'an Pharmaceutical's reach and reduce reliance on traditional distribution channels. The online healthcare market in China is experiencing rapid growth, with e-pharmacies and online consultations becoming increasingly popular. Investing in a user-friendly online platform and digital marketing could attract a new customer base. Timeline: 1 year.
- Research and Development: Investing in research and development to validate the efficacy and safety of its herbal formulations could enhance Tian'an Pharmaceutical's credibility and competitive advantage. Conducting clinical trials and publishing research findings in reputable journals could strengthen the company's reputation and attract partnerships with research institutions. This could also lead to the development of patented formulations, providing a unique selling proposition. Timeline: Ongoing.
What Are TNPH's Competitive Advantages?
- Proprietary herbal formulations.
- Established distribution network in China.
- Focus on traditional Chinese medicine.
- Brand recognition within its niche market.
What Does TNPH Do?
Founded in 2003 and headquartered in Xi'an, China, Tian'an Pharmaceutical Co., Ltd. specializes in the development, manufacture, and sale of traditional Chinese herbal medicines. The company's product portfolio includes a variety of formulations, such as pallets, hard capsules, and soft ointments, designed for the treatment and prevention of various diseases. Tian'an Pharmaceutical also engages in the research and development of biology goods and health care products, aiming to expand its offerings in the health and wellness sector. Key products include the Compound Ginseng capsule, used for treating prostate gland proliferation; Nizhuanle Yin granule, targeting stomach mucous membrane issues; and Tianan soft capsule, designed to improve blood vessel ventilation and reduce high blood fat levels. The company is also developing Tianan Pain Relief Capsule, intended for pain management related to joints, headaches, muscle injuries, cancer, gynecological disorders, and general pain. Tian'an Pharmaceutical distributes its products through independent distributors, who then supply pharmacies, drugstores, and hospitals across China. With a small team of 3 employees, the company focuses on leveraging traditional Chinese medicine to address specific health needs within its target market.
What Products and Services Does TNPH Offer?
- Develops traditional Chinese herbal medicines.
- Manufactures pallets, hard capsules, and soft ointments.
- Sells products for the treatment and prevention of diseases.
- Engages in research and development of biology goods.
- Creates health care products.
- Focuses on pharmaceutical and nutraceutical products.
- Sells products to independent distributors.
How Does TNPH Make Money?
- Develops and manufactures traditional Chinese medicine products.
- Sells products to independent distributors.
- Distributors sell products to pharmacies, drugstores, and hospitals.
What Industry Does TNPH Operate In?
Tian'an Pharmaceutical operates within the Drug Manufacturers - Specialty & Generic industry, which is characterized by intense competition and stringent regulatory requirements. The market for traditional Chinese medicine is substantial, driven by cultural preferences and a growing interest in natural remedies. However, this market is also subject to scrutiny regarding efficacy and quality control. The company competes with both domestic and international players, including those focusing on generic drugs and specialized herbal formulations. The industry is influenced by factors such as government healthcare policies, pricing pressures, and the increasing demand for innovative treatments.
Who Are TNPH's Key Customers?
- Independent distributors
- Pharmacies
- Drugstores
- Hospitals
Company Profile
Tian'an Pharmaceutical Co., Ltd. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Reno, US. The company is led by CEO Christopher T. G. Giordano. TNPH has traded publicly since 2007.
Financial Health
Tian'an Pharmaceutical Co., Ltd.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Tian'an Pharmaceutical Co., Ltd. stands at 5.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -67.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -0.1%, the inverse of the P/E and a quick read on earnings relative to price.
TNPH Valuation & Market Position
Relative to its peer group, TNPH's quantitative score of 42/100 is below the peer average of 62/100.
TNPH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialization in traditional Chinese medicine.
- Established distribution network in China.
- Proprietary herbal formulations.
- Focus on specific health conditions.
Bear Case
- Small company size with limited resources.
- High P/E ratio indicating high market expectations.
- Dependence on independent distributors.
- Limited geographic reach.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
TNPH Latest News
No recent news available for TNPH.
TNPH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TNPH.
Price Targets
Wall Street price target analysis for TNPH.
TNPH MoonshotScore
What does this score mean?
The MoonshotScore rates TNPH 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jianjun Weng
CEO
Jianjun Weng serves as the CEO of Tian'an Pharmaceutical Co., Ltd. His background includes experience in the pharmaceutical industry, with a focus on traditional Chinese medicine. He has been instrumental in guiding the company's strategic direction and product development efforts. His expertise lies in navigating the regulatory landscape and fostering relationships with distributors and healthcare providers. Prior to his role at Tian'an Pharmaceutical, Jianjun Weng held various positions in pharmaceutical sales and marketing.
Track Record: Under Jianjun Weng's leadership, Tian'an Pharmaceutical has focused on expanding its product line and strengthening its distribution network. He has overseen the development of new herbal formulations and the company's efforts to enhance its brand recognition. Key milestones include the launch of the Tianan soft capsule and the ongoing development of the Tianan Pain Relief Capsule. His strategic decisions have aimed to position the company as a key player in the traditional Chinese medicine market.
TNPH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Tian'an Pharmaceutical may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Lack of regulatory oversight.
- Higher risk of fraud or mismanagement.
- Verify the company's registration and legal status.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Research the background and experience of the company's management team.
- Check for any regulatory actions or legal disputes.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Company has been in operation since 2003.
- Focus on traditional Chinese medicine, which has a long history.
- Products are sold through independent distributors to pharmacies and hospitals.
- Development of multiple products for different health conditions.
TNPH Healthcare Stock FAQ
What does the AI Score mean for TNPH?
TNPH holds an AI Score of 42/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Tian'an Pharmaceutical Co., Ltd. is a Chinese company that develops, manufactures, and sells traditional Chinese herbal medicines. Their products target a range of conditions, from prostate issues …
What does Tian'an Pharmaceutical Co., Ltd. do?
Tian'an Pharmaceutical Co., Ltd. is a Chinese company specializing in the development, manufacture, and sale of traditional Chinese herbal medicines. Their product line includes various formulations like capsules, granules, and ointments designed to treat and prevent diseases. The company distributes these products through independent distributors, who then supply pharmacies, drugstores, and hospitals.
What do analysts say about TNPH stock?
As of 2026-03-16, there is no available analyst coverage for Tian'an Pharmaceutical Co., Ltd. given its OTC Other tier status and limited public information. The company's high P/E ratio of 1080.94 suggests that investors have high expectations for future growth, but this should be viewed cautiously due to the company's small size and limited resources.
What are the main risks for TNPH?
The main risks for Tian'an Pharmaceutical include its small size and limited resources, which could hinder its ability to compete with larger pharmaceutical companies. Regulatory changes in the pharmaceutical industry, particularly those affecting traditional Chinese medicine, could also pose a threat.
What are the key factors to evaluate for TNPH?
Tian'an Pharmaceutical Co., Ltd. (TNPH) holds an AI score of 42/100 (low). Tian'an Pharmaceutical operates in the niche market of traditional Chinese medicine, presenting both opportunities and challenges. Not financial advice.
How frequently does TNPH data refresh on this page?
TNPH's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TNPH's recent stock price performance?
Tian'an Pharmaceutical Co., Ltd. (TNPH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialization in traditional Chinese medicine. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TNPH overvalued or undervalued right now?
Tian'an Pharmaceutical Co., Ltd. (TNPH) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TNPH before investing?
Before investing in Tian'an Pharmaceutical Co., Ltd. (TNPH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's OTC status.
- AI analysis is pending and may provide further insights in the future.